AEON PRESS-RELEASE SEC Filing Analysis

Latest settled — T+20d ⚠ clustered

AEON ▲ +4.40% at T+20d

SHORT call ✗ call lost -4.40% · α vs SPY +4.59% · entry $0.9100 → $0.9500

Next anchor: T+60d in 17d

Currently $0.7150 · +21.43% from $0.9100 entry (call sign-flipped)

Entry anchored
Apr 2, 03:19 PM ET
via Databento tick

T+1d

+3.08%

call -3.08% · α -3.01%

$0.9380

settled 2mo ago

T+5d

-5.60%

call +5.60% · α +9.74%

$0.8590

settled 2mo ago

T+20d

+4.40%

call -4.40% · α +4.59%

$0.9500

settled 6w ago

T+60d

—

call — · α —

—

in 17d

Price Chart

Loading chart...

Executive Summary

AEON Biopharma received a notice from NYSE American that it is now non-compliant with an additional listing standard due to a stockholders' deficit of approximately $55 million as of December 31, 2025, and losses in three of its four most recent fiscal years. This follows a prior notice in February 2025 and does not immediately impact its listing, but the company must regain compliance by August 3, 2026, or face potential delisting. The situation reflects deteriorating financial health and heightened risk of exchange removal.

Actionable Insight

Traders should monitor AEON for potential delisting risk ahead of the August 3, 2026 deadline; any failure to show equity improvement or financing activity increases the likelihood of a forced OTC move, which typically triggers further price declines. The current market cap of $22M may not reflect imminent exchange risk.

Key Facts

AEON is now non-compliant with NYSE American's Section 1003(a)(ii), requiring $4.0 million in stockholders' equity due to losses in three of four recent fiscal years.
Stockholders' deficit was approximately $55 million as of December 31, 2025.
The company previously received a non-compliance notice in February 2025 under Section 1003(a)(i) and was given until August 3, 2026, to regain compliance.
Common stock continues to trade under 'AEON' with a '.BC' indicator denoting non-compliance.
Failure to regain compliance by August 3, 2026, or lack of progress during the plan period, could trigger delisting proceedings.

Financial Impact

Stockholders' deficit of $55 million as of year-end 2025; no revenue or earnings growth indicated

equitylisting statusinvestor confidence

Risk Factors

Risk of delisting if compliance is not achieved by August 3, 2026
Inability to raise capital to restore stockholders' equity
Continued operating losses exacerbating financial condition

Market Snapshot

Exchange

NYSE

Sector

Pharmaceutical Preparations

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3268136

5 reports for AEON

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for AEON — sortable, filterable
	Type				Now
May 14, 2026 29d ago	8-K NEUTRAL ★ 5/10	$0.7220 $0.7770	▲ +7.62%	▲ +6.65%	$0.7150 (−0.97%)
Apr 29, 2026 6w ago	DEFA14A NEUTRAL ★ 2/10	$0.9230 $0.9100	▼ −1.41%	▼ −3.14%	$0.7150 (−22.54%)
Apr 3, 2026 10w ago	8-K BEARISH ★ 8/10	$0.9100 $0.8590	▲ +5.60%	▲ +9.74%	$0.7150 (+21.43%)
Apr 3, 2026 10w ago	Press Release BEARISH ★ 7/10	$0.9100 $0.8590	▲ +5.60%	▲ +9.74%	$0.7150 (+21.43%)
Mar 30, 2026 10w ago	Press Release MIXED ★ 5/10	$0.9850 $0.9000	▼ −8.63%	▼ −12.57%	$0.7150 (−27.41%)

US Market Status

Market Closed — Opens Mon (49h 35m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access